Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07142707 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

StatusRecruiting
PhasePhase 1
Started2025-09-03
View on ClinicalTrials.gov ↗

Amendment history

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
2026-06-08
Study Status, Contacts/Locations v7
Study sitesdetails revised at 1 of 4 sites
2026-06-01
Study Status, Contacts/Locations v6
Study sites2→4
2026-04-23
Study Status, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility v5
Enrollment increased: 64 → 124 participants
Trial arms changed: 3 → 4
Primary completion pushed: 2026-05-30 → 2026-10-30
Completion pushed: 2026-05-30 → 2026-10-30
Eligibility criteriarevised
Inclusion Criteria: Age of >18 to ≤65 years at the time of signing the informed consent. Has a BMI of ≥30 to <4050 kg/m2 at screening and baseline. Weight-stable, i.e., no mo [...]
Study description+1 characters
[...] obesity, who are otherwise generally healthy. Approximately 64124 patients aged 18 to 65 years old will be enrolled.
2026-04-08
Study Status, Contacts/Locations v4
Study sites1→2
2025-12-08
Study Status v3
Re-verified, no change to tracked fields
2025-09-05
Study Status v2
Start dateestimated 2025-08-26→confirmed 2025-09-03
2025-08-19
Original filing
MBX Biosciences
5 trials monitored
See 1 trial at risk
Obesity
3,549 trials monitored
See 139 trials at risk
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Trial Details
NCT Number NCT07142707
Lead Sponsor MBX Biosciences
Conditions Obesity
Enrollment 124 participants
Start Date 2025-09-03
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-09